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ABSTRACT
Objectives Assess the efficacy and safety of 
tocilizumab in patients with systemic sclerosis (SSc) in a 
phase II study.
Methods patients with SSc were treated for 48 weeks 
in an open-label extension phase of the faSScinate 
study with weekly 162 mg subcutaneous tocilizumab. 
Exploratory end points included modified rodnan Skin 
Score (mrSS) and per cent predicted forced vital capacity 
(%pFVC) through week 96.
Results overall, 24/44 (55%) placebo-tocilizumab 
and 27/43 (63%) continuous-tocilizumab patients 
completed week 96. observed mean (Sd (95% CI)) 
change from baseline in mrSS was –3.1 (6.3 (–5.4 
to –0.9)) for placebo and –5.6 (9.1 (–8.9 to–2.4)) for 
tocilizumab at week 48 and –9.4 (5.6 (–8.9 to –2.4)) 
for placebo-tocilizumab and –9.1 (8.7 (–12.5 to –5.6)) 
for continuous-tocilizumab at week 96. of patients who 
completed week 96, any decline in %pFVC was observed 
for 10/24 (42% (95% CI 22% to 63%)) placebo-
tocilizumab and 12/26 (46% (95% CI 27% to 67%)) 
continuous-tocilizumab patients in the open-label period; 
no patients had >10% absolute decline in %pFVC. 
Serious infection rates/100 patient-years (95% CI) were 
10.9 (3.0 to 27.9) with placebo and 34.8 (18.0 to 60.8) 
with tocilizumab during the double-blind period by week 
48 and 19.6 (7.2 to 42.7) with placebo-tocilizumab and 
0.0 (0.0 to 12.2) with continuous-tocilizumab during the 
open-label period.
Conclusions Skin score improvement and FVC 
stabilisation in the double-blind period were observed in 
placebo-treated patients who transitioned to tocilizumab 
and were maintained in the open-label period. Safety 
data indicated increased serious infections in patients 
with SSc but no new safety signals with tocilizumab.
Trial registration number nCt01532869; results.
InTROduCTIOn
Systemic sclerosis (SSc) is a rare, debilitating 
autoimmune disorder of the connective tissue 
and vasculature that is characterised by inflam-
mation, fibrosis and microvascular injury of 
multiple organs.1–3 Patients with SSc experience 
high morbidity and mortality rates,2 particularly 
those who have pulmonary, cardiac or renal organ 
involvement.4 Indeed, lung disease is the primary 
cause of scleroderma-related deaths.1 5 Few treat-
ment options are available for patients with SSc, 
and there is an unmet need for disease-modifying 
therapy.6 
Interleukin 6 (IL-6) appears to play a role in SSc 
pathogenesis.7 8 Patients with SSc have increased 
IL-6 expression in endothelial cells and skin fibro-
blasts.9 Serum IL-6 levels are elevated in patients 
with SSc,10 11 particularly those with early diffuse 
cutaneous skin involvement.12 13 Furthermore, 
some studies have suggested a role for IL-6 as a 
marker for disease progression and clinical outcome 
in patients with SSc.11 C reactive protein (CRP) is 
correlated with IL-6, and CRP levels are elevated in 
patients with active SSc, especially those with early 
diffuse cutaneous SSc.14
Tocilizumab is a monoclonal anti–IL-6 receptor-α 
antibody for the treatment of patients with rheuma-
toid arthritis, systemic juvenile idiopathic arthritis, 
polyarticular juvenile idiopathic arthritis and giant 
cell arteritis.15 Initial investigations of tocilizumab 
in patients with SSc demonstrated improvements in 
skin sclerosis and SSc-associated polyarthritis.16 17 
The faSScinate clinical trial was the first double-
blind, randomised controlled trial investigating the 
efficacy and safety of subcutaneous tocilizumab in 
patients with SSc. Results from the 48-week double-
blind period of faSScinate, including the primary 
end point, were published previously and demon-
strated that treatment with tocilizumab resulted 
in a clinically meaningful but not statistically 
significant decline in modified Rodnan Skin Score 
(mRSS) compared with placebo through week 48 
for patients receiving tocilizumab.18 Exploratory 
efficacy results and safety through week 96 of the 
faSScinate trial, including the 48-week open-label 
period, are now reported.
MeThOdS
Study design
faSScinate was a multicentre, randomised, double-
blind, placebo-controlled, two-arm, parallel-group, 
phase II clinical trial conducted at 35 hospitals 
across Canada, France, Germany, the UK and 
USA. The study design and patient enrolment 
criteria have been published.18 Briefly, the 96-week 
trial consisted of a 48-week double-blind period 
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followed by a 48-week open-label period. Patients were randomly 
assigned (1:1) to receive weekly subcutaneous injections of 
tocilizumab 162 mg or placebo during the 48-week double-blind 
period (tocilizumab group or placebo group, respectively) with 
the option for escape therapy with methotrexate, hydroxychlo-
roquine or mycophenolate mofetil (MMF) after 24 weeks if they 
had worsening SSc. Randomisation was stratified according to 
joint involvement at baseline (<4 or ≥4 joints on the 28 tender 
joint count). At week 48, all patients in the tocilizumab and 
placebo groups transitioned to open-label weekly injections of 
tocilizumab 162 mg for another 48 weeks (continuous-tocili-
zumab and placebo-tocilizumab groups, respectively).
Patients
Eligible patients were 18 years of age or older; received a diag-
nosis of SSc according to the 1980 American College of Rheu-
matology Criteria,19 with less than 5 years since their first 
non-Raynaud’s sign or symptom; had an mRSS score of 15 to 40 
with clinical skin involvement proximal to the elbows, knees or 
both, with or without facial involvement; and had active disease. 
Active disease was defined as at least one of the following features 
at screening: increase ≥3 in mRSS units compared with the last 
visit within the previous 1 month to 6 months or new-onset SSc 
within 1 year before screening, involvement of one new body 
area with ≥2 mRSS units or two new body areas with ≥1 mRSS 
unit, documentation of worsening skin thickening (patients 
with new-onset SSc only), or ≥1 tendon friction rub plus CRP 
level ≥10 mg/L, erythrocyte sedimentation rate ≥28 mm/hour 
or platelet count ≥330 × 103/µL. All patients provided written 
informed consent.
Assessments
Exploratory efficacy end points included mean change from 
baseline to week 96 in mRSS; proportions of patients with 
improvements in mRSS of ≥20%, ≥40% and ≥60%; propor-
tions of patients achieving minimal clinically important differ-
ence (MCID) in mRSS (change from baseline of ≥4.7)20; 
per cent predicted forced vital capacity (%pFVC); per cent 
predicted diffusing capacity for carbon monoxide corrected for 
haemoglobin (%pDLCO (Hb corr)) and Clinician Global Visual 
Analogue Scale (VAS). Patient-reported outcomes included 
Health Assessment Questionnaire–Disability Index (HAQ-DI), 
Patient Global VAS, Functional Assessment of Chronic Illness 
Therapy (FACIT)-Fatigue Score and Pruritus 5-D Itch Scale. 
Safety was reported as rates of adverse events (AEs) and serious 
AEs (SAEs) per 100 patient-years (PY) with 95% CIs.
Statistical analysis
Although a mixed-model, repeated-measures analysis was 
performed on the placebo-controlled period at weeks 24 and 
48, observed data were analysed for the week 96 period because 
all end points during the open-label period were exploratory. 
Exploratory efficacy end points in the open-label period were 
assessed in the modified intent-to-treat population (all randomly 
assigned patients who received any study drug). Safety was 
Figure 1 Patient disposition (intent-to-treat population). *Methotrexate, n=5; hydroxychloroquine, n=2; mycophenolate mofetil, n=5. 
†Methotrexate, n=2; hydroxychloroquine, n=2; mycophenolate mofetil, n=1. ‡One patient who continued as an escape patient at week 4818 was later 
removed by the site and was not included at week 96. §Methotrexate, n=1; hydroxychloroquine, n=1; mycophenolate mofetil, n=4 (1 patient who 
received mycophenolate mofetil in the double-blind period and received it again in the open-label period was not counted in the open-label period). 
¶Hydroxychloroquine, n=2; mycophenolate mofetil, n=2. OL, open-label; QW, every week; SC, subcutaneously; TCZ, tocilizumab.
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assessed in all patients who received study drug and provided 
at least one safety assessment after treatment (safety population) 
and was summarised by treatment received. The study was not 
designed or powered for formal statistical comparison of the two 
treatment arms within the open-label period or with the original 
tocilizumab arm at week 48 because of inherent biases of open-
label results. However, 95% CIs were calculated as descriptive 
statistics using the Pearson Clopper method for exact binomial, 
and CIs for rates of AEs were based on Poisson distribution.21 
Data from escape patients were not censored.
ReSulTS
Patients
Eighty-seven patients were enrolled in the faSScinate trial 
(figure 1); in the double-blind period, 44 patients were origi-
nally assigned to receive weekly subcutaneous placebo (placebo 
group) and 43 patients were originally assigned to receive weekly 
subcutaneous tocilizumab 162 mg (tocilizumab group). At week 
48, 31 (70.5%) patients originally assigned to double-blind 
placebo transitioned to open-label weekly tocilizumab 162 mg 
(placebo-tocilizumab group) and 30 (69.8%) patients originally 
assigned to double-blind tocilizumab transitioned to open-label 
weekly subcutaneous tocilizumab 162 mg (continuous-tocili-
zumab group) until they completed the study or withdrew from 
treatment. Twenty-four (54.5%) patients in the placebo-tocili-
zumab group and 27 (62.8%) patients in the continuous-tocili-
zumab group completed week 96. During the open-label period, 
five patients discontinued because of AEs (four patients in the 
placebo-tocilizumab group and one patient in the continuous-to-
cilizumab group). Other reasons for study withdrawal were 
non-compliance (one patient in the placebo-tocilizumab group), 
lack of efficacy (one patient in each treatment group) and patient 
consent withdrawn (one patient in each treatment group). 
Escape therapy was received by 18 patients originally assigned to 
receive placebo (12 in the placebo group during the double-blind 
period and 6 in the placebo-tocilizumab group during the open-
label period) and by 9 patients originally assigned to receive 
tocilizumab (5 in the tocilizumab group during the double-blind 
period and 4 in the continuous-tocilizumab group during the 
open-label period) (figure 1).
Baseline characteristics were similar between patients who were 
randomly assigned in the double-blind period and those who tran-
sitioned to open-label treatment, with the exception of HAQ-DI 
scores and CRP values, which were numerically lower, on average, 
in patients who transitioned to the open-label period (table 1).
efficacy
Improvements in mRSS were observed during the double-blind 
period with tocilizumab treatment (mean (SD; 95% CI) change 
from baseline to week 48: –5.6 (9.1; –8.9 to –2.4)). In addition 
to the –5.6 improvement from baseline to week 48 with tocili-
zumab treatment, further improvement was seen in the open-
label period, bringing the total mean improvement to –9.1 (8.7; 
–12.5 to –5.6) from baseline to week 96 (figure 2). Furthermore, 
patients in the placebo group experienced similar improvements 
after receiving open-label tocilizumab from week 48 to week 96 
(figure 2) (mean (SD; 95% CI) change from baseline –3.1 (6.3; 
–5.4 to –0.9) to week 48 during double-blind placebo treatment 
and –9.4 (5.6; –11.8 to –7.0) to week 96 after 48 weeks of open-
label tocilizumab treatment). There were incremental improve-
ments between weeks 48 and 96 in the proportions of patients 
who experienced improvements in mRSS of ≥20%, ≥40% and 
Table 1 Baseline demographics and disease characteristics (safety population)
Patients randomly assigned in the double-blind period Patients who transitioned to the open-label period*
Placebo QW SC
n=44
Tocilizumab 162 mg QW SC
n=43
Placebo- tocilizumab 162 mg 
QW SC
n=31
Continuous-tocilizumab 162 mg 
QW SC
n=30
Age, years 48 (12.9) 51 (11.7) 47 (11.9) 52 (11.8)
Female, n (%) 35 (80) 32 (74) 26 (84) 23 (77)
White, n (%) 40 (91) 38 (88) 28 (90) 26 (87)
Duration of SSc, months 19.5 (17.0) 17.6 (13.9)§ 20.0 (18.2) 17.7 (13.5)
Total mRSS† 25.6 (5.9) 26.4 (7.2) 24.6 (5.4) 25.2 (6.9)
TJC28 7.4 (8.5)‡ 7.4 (8.9) 8.3 (9.1) 8.1 (10.0)
TJC28 ≥4, n (%) 21 (49)‡ 20 (47) 16 (52) 12 (40)
Overall HAQ-DI Score 1.4 (0.7) 1.3 (0.6)§ 1.2 (0.7) 1.2 (0.6)¶
Clinician Global VAS, mm 60.9 (15.2) 64.1 (15.1) 57.9 (15.2) 62.5 (15.7)
Patient Global VAS, mm 61.9 (21.0) 59.8 (18.3) 60.2 (22.9) 56.6 (18.3)
FACIT-Fatigue 26.5 (11.6)‡ 25.6 (11.4) 27.9 (12.1)** 26.2 (10.5)
Pruritus 5-D Itch 13.5 (5.1)‡ 13.1 (4.5)§ 13.2 (4.8)** 13.0 (4.2)¶
CRP, mg/L 10.3 (13.5)‡ 10.0 (13.5) 7.7 (7.2) 7.4 (12.7)
%pFVC 82 (13)§ 80 (14) 83 (14)** 78 (13)
%pDLCO (Hb corr) 74 (21)‡ 73 (19)§ 75 (23)** 73 (17)
All values are mean (SD) unless stated otherwise.
*Original baseline data for patients who entered the OL period.





%pDLCO (Hb corr), per cent predicted diffusing capacity of the lung for carbon monoxide corrected for haemoglobin; %pFVC, per cent predicted forced vital capacity; CRP, C 
reactive protein; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire–Disability Index; mRSS, modified Rodnan Skin Score; QW, 
every week; SC, subcutaneously; SSc, systemic sclerosis; TJC28, tender joint count based on 28 joints; ULN, upper limit of normal; VAS, Visual Analogue Scale.
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≥60% and change in mRSS equal to or greater than the MCID 
of 4.7 units in the continuous-tocilizumab group (table 2).
Improvements in Clinician Global VAS and patient-reported 
outcomes, as indicated by negative change in HAQ-DI, Clini-
cian Global VAS, and Patient Global VAS and positive change 
in FACIT-Fatigue Score, observed at week 48 in the tocilizumab 
group were maintained through the open-label period in the 
continuous-tocilizumab group (table 2). Furthermore, greater 
improvements in patient-reported outcomes were observed in 
placebo-tocilizumab patients after they switched to tocilizumab 
during the open-label period than during the double-blind 
placebo period. Patients in the placebo group experienced mean 
(95% CI) changes from baseline in HAQ-DI of 0.17 (0.05 to 
0.30) after 48 weeks of double-blind placebo treatment and –0.29 
(–0.46 to –0.13) at week 96 after 48 weeks of open-label tocili-
zumab treatment (placebo-tocilizumab). Changes from baseline in 
Clinician Global VAS were –7.69 (–15.06 to –0.32) and –20.61 
(–29.52 to –11.7), respectively, changes in Patient Global VAS were 
–4.03 (–12.42 to 4.36) and –23.75 (–38.95 to –3.46), respectively, 
and changes in FACIT-Fatigue Scores were 1.37 (–1.37 to 4.11) and 
11.26 (5.72 to 16.81), respectively.
Among patients who completed the study to week 96 (completers 
analysis), similar proportions in both treatment groups experienced 
worsening in %pFVC (figure 3); 42% of patients in the placebo-to-
cilizumab group and 46% of patients in the continuous-tocilizumab 
group had absolute decreases (>0) in %pFVC during the open-
label period from weeks 48 to 96 compared with 83% of patients 
receiving placebo and 54% of patients receiving tocilizumab during 
the double-blind period from weeks 0 to 48. During the open-label 
period, no patients in either treatment group who completed week 
96 or withdrew experienced >10% absolute decline in %pFVC 
after receiving tocilizumab, in contrast to three in the placebo group 
and one in the tocilizumab group during the double-blind period.
Safety
SAE rates (95% CIs) were 76.1 (50.6–110.0) in the placebo 
group and 66.7 (42.3–100.1) in the tocilizumab group by week 
Figure 2 Mean change (95% CI) in mRSS from baseline to week 96 (intent-to-treat population; observed data). Negative values denote 
improvement. Patients randomly assigned to PBO 162 mg QW SC received OL TCZ 162 mg QW SC from week 48. BL, baseline; DB, double-blind; mRSS, 
modified Rodnan Skin Score; OL, open-label; PBO, placebo; %pFVC, per cent predicted forced vital capacity; QW, every week; SC, subcutaneously; TCZ, 
tocilizumab.
group.bmj.com on November 21, 2017 - Published by http://ard.bmj.com/Downloaded from 
5Khanna D, et al. Ann Rheum Dis 2017;0:1–9. doi:10.1136/annrheumdis-2017-211682
Clinical and epidemiological research
48 compared with 36.0 (18.0–64.4) in the placebo-tocilizumab 
group and 16.5 (5.4–38.5) in the continuous-tocilizumab group 
from week 48 to week 96 (table 3). Infections were the most 
frequently reported AEs and SAEs during double-blind tocili-
zumab treatment and in placebo patients who transitioned to 
open-label tocilizumab. In the placebo-tocilizumab group, rates 
of serious infection increased after the switch to open-label 
tocilizumab; the rate (95% CI) of serious infections was 10.9 
(3.0–27.9) per 100 PY during the 48 weeks of double-blind 
placebo treatment compared with 19.6 (7.2–42.7) per 100 PY 
from week 48 to 96, with four patients (12.9%) in this group 
reporting at least one serious infection after switching to open-
label tocilizumab (see online supplementary appendix table  1 
for details of serious infections). Patients in the tocilizumab 
group had a serious infection rate of 34.8 (95% CI 18.0 to 60.8) 
per 100 PY by week 48. No serious infections were reported 
after the switch from double-blind to open-label tocilizumab 
(continuous-tocilizumab).
No deaths were reported during the open-label period in either 
treatment group, and no serious hepatic AEs, anaphylactic reac-
tions, gastrointestinal perforations or demyelination SAEs were 
reported during the 96-week treatment period. Changes in labo-
ratory parameters of interest for tocilizumab, including alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) 
levels, neutrophil counts and platelet counts, were usually ≤5× the 
upper limit of normal (ULN) over the 96-week treatment period. 
Table 2 Change from baseline to week 48 (double-blind period) or week 96 (including open-label period) in exploratory end points (intent-to-
treat population; observed data)





162 mg QW SC
n=43
Placebo- tocilizumab
162 mg QW SC
n=31
Continuous-tocilizumab
162 mg QW SC
n=30
Change from baseline in mRSS, n (% (95% CI))*
  ≥ 20% 13 (29.5 [16.8 to 45.2]) 18 (41.9 [27.0 to 57.9]) 18 (40.9 [26.3 to 56.8]) 22 (51.2 [35.5 to 66.7])
  ≥ 40% 3 (6.8 [1.4 to 18.7]) 10 (23.3 [11.8 to 38.6]) 13 (29.5 [16.8 to 45.2]) 15 (34.9 [21.0 to 50.9])
  ≥ 60% 0 (0.0 [0.0 to 8.0]) 5 (11.6 [3.9 to 25.1]) 7 (15.9 [6.6 to 30.1]) 6 (14.0 [5.3 to 27.9])
  ≥4.7 units (MCID)20 12 (27.3 [15.0, 42.8]) 
n=33
18 (41.9 [27.0, 57.9]) 
n=32
19 (43.2 [28.3, 59.0]) 
n=24
22 (51.2 [35.5, 66.7]) 
n=27
TJC28, mean (95% CI) change from baseline –0.97 (–2.85 to 0.91) –2.28 (–4.16 to –0.40) –4.88 (–7.99 to –1.76) –3.39 (–6.14 to –0.65)








HAQ-DI, mean (95% CI) change from 
baseline†
0.17 (0.05 to 0.30) –0.01 (–0.25 to 0.23) –0.29 (–0.46 to –0.13) –0.13 (–0.33 to 0.08)








Clinician Global VAS, mean (95% CI) change 
from baseline†
–7.69 (–15.06 to –0.32) –18.57 (–26.89 to –10.25) –20.61 (–29.52 to –11.7) –21.30 (–31.05 to –11.54)








Patient Global VAS, mean (95% CI) change 
from baseline†
–4.03 (–12.42 to 4.36) –9.13 (–18.68 to 0.43) –23.75 (–38.95 to –8.55) –11.11 (–18.75 to –3.46)








FACIT-Fatigue score, mean (95% CI) change 
from baseline†
1.37 (–1.37 to 4.11) 3.69 (0.34 to 7.04) 11.26 (5.72 to 16.81) 4.15 (1.51 to 6.79)








Pruritus 5-D Itch Score, mean (95% CI) 
change from baseline†
–1.87 (–3.26 to –0.48) –2.03 (–3.91 to –0.16) –4.43 (–6.32 to –2.55) –3.23 (–5.38 to –1.09)








%pFVC, mean (95% CI) change from 
baseline
–0.06 (–0.10 to –0.03) –0.02 (–0.04 to 0.00) –0.03 (–0.07 to 0.01) –0.01 (–0.03 to 0.02)








% pDLCO (Hb corr), mean (95% CI) change 
from baseline
–0.03 (–0.07 to 0.01) –0.03 (–0.06 to 0.00) –0.03 (–0.10 to 0.05) –0.03 (–0.08 to 0.01)








n denotes number of patients with valid assessments at the time point. Escape data were not censored.
*Percentages were calculated based on n=43 (tocilizumab) and n=44 (placebo), the intent-to-treat population; thus, patients with missing change in mRSS Scores were 
considered non-responders.
†Negative change from baseline indicated improvement for all efficacy measures except FACIT-Fatigue, FVC and DLCO, for which positive change from baseline indicated 
improvement.
%pDLCO (Hb corr), per cent predicted diffusing capacity of lung for carbon monoxide corrected for haemoglobin; %pFVC, per cent predicted forced vital capacity; FACIT, 
Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire–Disability Index; max, maximum; MCID, minimal clinically important difference; min, 
minimum; mRSS, modified Rodnan Skin Score; QW, every week; SC, subcutaneously; TJC28, tender joint count based on 28 joints; VAS, Visual Analogue Scale.
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ALT elevation >5× ULN was reported in one patient receiving 
placebo and one patient receiving tocilizumab during the double-
blind period and one placebo-tocilizumab patient after switching to 
open-label tocilizumab. AST elevation >5× ULN was reported in 
one patient receiving placebo during the double-blind period (see 
online supplementary appendix table 2).
dISCuSSIOn
The phase II faSScinate Study was the first double-blind, 
randomised controlled trial to show evidence of a potential 
disease-modifying effect in patients with SSc. By week 48, at 
the end of the double-blind period of the study, treatment with 
tocilizumab was associated with clinically relevant, though not 
statistically significant, improvements in skin thickness measured 
by mRSS and lung function measured by %pFVC.18 It has been 
suggested that tocilizumab may be the first efficient, molecularly 
targeted treatment for patients with SSc.22
Results from the open-label period of the faSScinate trial show 
that patients originally assigned to receive placebo in the double-
blind period who transitioned to open-label tocilizumab at week 
48 experienced improvements in mRSS by week 96 that were 
similar to those of patients who received tocilizumab throughout 
the study. Furthermore, patients originally assigned to receive 
tocilizumab during the double-blind period maintained and 
continued the improvements in mRSS observed during the first 
48 weeks of treatment on receiving another 48 weeks of open-
label tocilizumab. Although the mean change in mRSS appeared 
to flatten from week 72 in the continuous-tocilizumab group, 
Figure 3 Cumulative distribution plot of change from baseline in %pFVC (completers analysis). Data for TCZ 162 mg QW SC and PBO 162 mg QW 
SC treatment groups show change from baseline to week 48. Patients receiving PBO-TCZ 162 mg QW SC and continuous-TCZ 162 mg QW SC started 
OL TCZ from week 48 (mean (SD) %pFVC at week 48 was 0.78 (0.14) for the PBO group and 0.80 (0.11) for the TCZ group), and change from week 48 
to week 96 is shown. Only patients with data at week 96 are included in any arm (completers); one completer had a missing FVC assessment at week 
96 and was excluded from the completers analysis. DB, double-blind; OL, open-label; PBO, placebo; %pFVC, per cent predicted forced vital capacity; 
QW, every week; SC subcutaneously; TCZ, tocilizumab.
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there were improvements for individual patients between weeks 
72 and 96. Of the 27 patients receiving continuous tocilizumab 
who completed the study through week 96, 14/27 (52%) had 
further, primarily modest, improvements (range, −1 to −8 
change in mRSS). However, there were two outliers who expe-
rienced considerable worsening (+9 and+14 change in mRSS) 
during this period. Overall, this culminates in a flattened average 
response. The potential for improvement may be more limited 
at this time point; 7/27 (26%) patients among the contin-
uous tocilizumab completers had observed mRSS scores ≤9 at 
week 72 compared with 2/24 (8%) among the placebo-tocili-
zumab group.
Improvements from weeks 48 to 96 in mRSS were supported 
by improvements in patient-reported outcomes, including 
HAQ-DI, Patient Global VAS and FACIT-Fatigue Scores, 
observed in patients initially assigned to placebo who transi-
tioned to open-label tocilizumab and were comparable to those of 
patients who received tocilizumab continuously, consistent with 
trends observed with tocilizumab treatment during the double-
blind period.18 Consistent as well with exploratory analyses 
in the double-blind period showing fewer tocilizumab-treated 
(10%) than placebo-treated (23%) patients experienced abso-
lute decline (>10%) in %pFVC after 48 weeks,18 no patients 
who completed week 96 of the study experienced >10% decline 
in %pFVC during the open-label period while receiving tocili-
zumab. Of note, the primary end point was change in mRSS, 
and, at the time the study was designed, the patient populations 
had not been enriched for patients with SSc-associated intersti-
tial lung disease.
Safety results over the 96-week treatment period were 
consistent with the known safety profile of tocilizumab; infec-
tions were the most frequently reported AEs and SAEs, and an 
increased rate of serious infections was observed after patients 
transitioned from placebo to tocilizumab. AEs tended to occur 
more frequently in the first few months after patients transi-
tioned from placebo to tocilizumab but less frequently in longer-
term follow-up. Infections were the most frequently reported 
SAEs in clinical trials of tocilizumab in patients with rheumatoid 
arthritis (RA).23 24 Rates of SAEs and serious infections in this 
study in patients with SSc were approximately five times and 
eight times higher, respectively, than those reported in patients 
with RA,23 24 which is expected given the high morbidity and 
mortality in patients with SSc.1 The frequencies of SAEs and 
serious infections observed in faSScinate are consistent with 
those in other SSc studies.25–27 Patients with SSc may be prone to 
digital ulcers,1 and complications of digital ulcers occur in 15% 
Table 3 Adverse events (AEs, safety population)





162 mg QW SC
n=43
Placebo-tocilizumab
162 mg QW SC
n=31
Continuous-tocilizumab
162 mg QW SC
n=30
Exposure, PY 36.8 34.5 30.6 30.3
AEs, n 244 283 126 153
  Rate/100 PY (95% CI) 663.5 (582.9 to 752.2) 820.6 (727.8 to 922.0) 412.4 (343.5 to 491.0) 504.4 (427.6 to 590.9)
SAEs, n 28 23 11 5
  Rate/100 PY (95% CI) 76.1 (50.6 to 110.0) 66.7 (42.3 to 100.1) 36.0 (18.0 to 64.4) 16.5 (5.4 to 38.5)
  Patients with ≥1 SAE, n (%) 16 (36.4) 14 (32.6) 7 (22.6) 4 (13.3)
  Patients with ≥1 serious infection, n (%)* 3 (6.8) 9 (20.9) 4 (12.9) 0
AEs leading to death, n 1 3 0 0
  Rate/100 PY 2.72 8.70 0.00 0.00
Patients with AEs leading to withdrawal, n (%) 5 (11.4) 6 (14.0) 4 (12.9)† 0
  Rate/100 PY 13.60 17.40 13.09 0.00
Patients with injection site reactions, n* 2 (4.5) 3 (7.0) 4 (12.9) 1 (3.3)
SAEs according to system organ class,‡ number of events (rate/100 PY [95% CI])
  Infections and infestations 4 (10.9 [3.0 to 27.9]) 12 (34.8 [18.0 to 60.8]) 6 (19.6 [7.2 to 42.7]) 0 (0.0 [0.0 to 12.2])
  Cardiac disorders 5 (23.6 [4.4 to 31.7]) 1 (2.9 [0.1 to 16.2]) 0 (0.0 [0.0 to 12.1]) 1 (3.3 [0.1 to to 18.4])
  Gastrointestinal disorders 6 (16.3 [6.0 to 35.5]) 1 (2.9 [0.1 to 16.2]) 0 (0.0 [0.0 to 12.1]) 0 (0.0 [0.0 to 12.2])
  Musculoskeletal and connective tissue disorders 2 (5.4 [0.7 to 19.7]) 2 (5.8 [0.7 to 21.0]) 1 (3.3 [0.1 to 18.2]) 0 (0.0 [0.0 to 12.2])
  Skin and subcutaneous tissue disorders 2 (5.4 [0.7 to 19.7]) 2 (5.8 [0.7 to 21.0]) 0 (0.0 [0.0 to 12.1]) 1 (3.3 [0.1 to 18.4])
  Vascular disorders 4 (10.9 [3.0 to 27.9]) 1 (2.9 [0.1 to 16.2]) 0 (0.0 [0.0 to 12.1]) 0 (0.0 [0.0 to 12.2])
  Blood and lymphatic system disorders 1 (2.7 [0.1 to 15.2]) 1 (2.9 [0.1 to 16.2]) 1 (3.3 [0.1 to 18.2]) 0 (0.0 [0.0 to 12.2])
  Renal and urinary disorders 2 (5.4 [0.7 to 19.7]) 0 (0.0 [0.0 to 10.7]) 1 (3.3 [0.1 to 18.2]) 0 (0.0 [0.0 to 12.2])
  General disorders and administration site conditions 0 (0.0 [0.0 to 10.0]) 2 (5.8 [0.7 to 21.0]) 0 (0.0 [0.0 to 12.1]) 0 (0.0 [0.0 to 12.2])
  Neoplasms, benign, malignant and unspecified 0 (0.0 [0.0 to 10.0]) 0 (0.0 [0.0 to 10.7]) 1 (3.3 [0.1 to 18.2]) 1 (3.3 [0.1 to 18.4])
  Nervous system disorders 2 (5.4 [0.7 to 19.7]) 0 (0.0 [0.0 to 10.7]) 0 (0.0 [0.0 to 12.1]) 0 (0.0 [0.0 to 12.2])
  Endocrine disorders 0 (0.0 [0.0 to 10.0]) 0 (0.0 [0.0 to 10.7]) 0 (0.0 [0.0 to 12.1]) 1 (3.3 [0.1 to 18.4])
  Psychiatric disorders 0 (0.0 [0.0 to 10.0]) 1 (2.9 [0.1 to 16.2]) 0 (0.0 [0.0 to 12.1]) 0 (0.0 [0.0 to 12.2])
  Reproductive system and breast disorders 0 (0.0 [0.0 to 10.0]) 0 (0.0 [0.0 to 10.7]) 0 (0.0 [0.0 to 12.1]) 1 (3.3 [0.1 to 18.4])
  Respiratory, thoracic and mediastinal disorders 0 (0.0 [0.0 to 10.0]) 0 (0.0 [0.0 to 10.7]) 1 (3.3 [0.1 to 18.2]) 0 (0.0 [0.0 to 12.2])
*Multiple occurrences in the same patient are counted once.
†Osteomyelitis (one case serious, one case not serious), scleroderma renal crisis and breast cancer metastatic.
‡According to the Medical Dictionary for Regulatory Activities, version 18.0.
AEs, adverse events; PY, patient-years; QW, every week; SAEs, serious adverse events; SC, subcutaneously.
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of patients with SSc.28 The occurrence of two cases of infected 
digital ulcers and one of osteomyelitis in patients who transi-
tioned from placebo to open-label tocilizumab suggested that 
tocilizumab may increase infections in patients with SSc-asso-
ciated digital ulcers, likely over pressure areas such as proximal 
interphalangeal joints.
The present study had some important limitations. First, all 
patients received open-label tocilizumab after week 48; therefore, 
the data collected during the open-label period were uncontrolled. 
There was a high discontinuation rate. During the open-label 
period, 7 of the 31 (23%) patients originally assigned to placebo 
who entered the open-label period and 3 of the 30 (10%) patients 
originally assigned to tocilizumab who entered the open-label 
period withdrew from the study. The discontinuation rate from 
48 to 96 weeks (16%) was lower than it was in the first 48 weeks 
of the study (28%). Overall, 63% of patients originally assigned 
to receive tocilizumab and 55% of patients originally assigned to 
receive placebo completed the full 96 weeks of treatment. It is likely 
that patients who completed week 48 and entered the open-label 
period were less ill or responded better to treatment and perhaps 
had already experienced more improvement. This selection bias is 
a common problem associated with open-label, long-term exten-
sion studies.29 Withdrawal of patients who experience AEs leads 
to the selection of healthier patients, which should be considered 
when interpreting the longer-term rates of AEs and SAEs. Second, 
patients with elevated acute-phase reactants were enrolled in this 
study; therefore, further studies may be needed to investigate the 
efficacy and safety of tocilizumab in other patient subsets. Third, 
given the limited numbers of patients with serious infections, anal-
ysis of the data to identify potential risk factors, in particular for 
any interaction of risk factors with tocilizumab, would be under-
powered and was not performed. A phase III study with a larger 
sample size is under way. Last, another limitation is that the study 
was not designed or powered for formal statistical comparison of 
the two treatment arms during the open-label period, and formal 
testing of this exploratory data was not prespecified. For the same 
reason, a comparison of placebo patients who completed the open-
label phase with those in the tocilizumab treatment arm at week 
48 is not appropriate. Therefore, although trends can be observed, 
comparative analyses could not be interpreted in a meaningful way, 
and formal statistical testing was not feasible.
No disease-modifying therapies have been approved for the 
treatment of patients with SSc, but some may control symptoms. 
Treatment options for patients with SSc are largely dependent 
on the organs affected.30 31 For example, cyclophosphamide has 
demonstrated improvement32 or trends for improvement33 in lung 
function in patients with SSc and interstitial lung disease, though 
its use has been associated with significant toxicity.30 Similarly, stem 
cell transplantation has resulted in improvements in skin fibrosis 
and prevention of lung decline and mortality but is associated with 
significant costs and risks.34–36 Methotrexate has demonstrated 
trends for improvement in skin scores in randomised controlled 
trials in patients with early SSc.37 38 Recently, MMF has shown 
efficacy similar to that of cyclophosphamide for lung and skin 
fibrosis.39 40 Tocilizumab may be the first targeted agent to show 
benefit in the amelioration of skin sclerosis and the prevention of 
pulmonary decline in patients with SSc.18
Overall, the open-label results of the faSScinate study support 
observations reported from the double-blind period in that the 
placebo and tocilizumab groups improved similarly when placebo 
patients were switched to active treatment. Further studies are 
required to investigate the efficacy and safety of tocilizumab in the 
treatment of patients with SSc and to determine whether tocili-
zumab produces significant improvement in skin sclerosis and 
stabilisation of lung function. A double-blind, phase III randomised 
controlled trial (NCT02453256) will investigate the efficacy and 
safety of tocilizumab compared with placebo in a 48-week double-
blind period and a 48-week open-label period to further investi-
gate the findings of the phase II faSScinate trial.
In conclusion, together with the results from the first 48 weeks 
of double-blind treatment,18 results from the open-label period 
of the faSScinate trial suggest that treatment with tocilizumab is 
associated with benefits for skin fibrosis, lung fibrosis and phys-
ical function in patients with SSc but increased risk for serious 
infections. Tocilizumab may be a promising targeted therapy for 
patients with progressive SSc who have few treatment options.
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